PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol

morningstar.com·May 25, 2026 · 8 g fa

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

medpagetoday.com·May 26, 2026 · 6 g fa

So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia

spectator.com·May 26, 2026 · 7 g fa

Gene-editing drugs are opening a new frontier in medicine

arstechnica.com·May 28, 2026 · 5 g fa

Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial

arstechnica.com·May 28, 2026 · 5 g fa

One dose of gene-editing drug cut bad cholesterol 62% for months in small trial

endpoints.news·May 26, 2026 · 7 g fa

Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout

statnews.com·May 25, 2026 · 8 g fa

Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study

biopharmadive.com·May 26, 2026 · 7 g fa

Early data for heart drug affirm Lilly’s billion-dollar bet on Verve

benzinga.com·May 26, 2026 · 7 g fa

Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L

gulfnews.com·May 31, 2026 · 2 g fa

Why researchers are excited about a one-time cholesterol therapy